Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01845740 · ClinicalTrials.gov registry record · Phase 1
Phase Ib Study of SC Milatuzumab in SLE
A Phase 1 study of Lupus Nephritis and Lupus Erythematosus, Systemic, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT01845740 is a Phase 1 study of Lupus Nephritis and Lupus Erythematosus, Systemic that has completed, run by Gilead Sciences. The registered enrollment target is 22 participants, below the 310-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01845740, a Phase 1 study of Lupus Nephritis and Lupus Erythematosus, Systemic, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
Milatuzumab will be given subcutaneously at different dose levels once (depending on the dose level) for 4 weeks to determine if milatuzumab helps to control lupus (SLE).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG milatuzumab
Study Locations (1)
California
- Cedars Sinai Medical Center-Wallace Rheumatic Study Center - West Hollywood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2007-01 |
| Est. Completion | 2009-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01845740
The ClinicalTrials.gov registry entry for NCT01845740 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 310-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (93% lower). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Lupus Nephritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01845740 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01845740 about?
NCT01845740 is a clinical study titled "Phase Ib Study of SC Milatuzumab in SLE". Milatuzumab will be given subcutaneously at different dose levels once (depending on the dose level) for 4 weeks to determine if milatuzumab helps to control lupus (SLE).
What is the current status of trial NCT01845740?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2007-01. Estimated completion is 2009-06.
What conditions does trial NCT01845740 study?
This clinical trial studies the following conditions: Lupus Nephritis, Lupus Erythematosus, Systemic, Lupus Erythematosus, Discoid, Lupus Erythematosus, Cutaneous, Lupus Vasculitis, Central Nervous System.
What interventions are being tested in trial NCT01845740?
The interventions under investigation include: Placebo (DRUG), milatuzumab (DRUG).
Who is sponsoring clinical trial NCT01845740?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01845740 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lupus Nephritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
RECRUITING · Phase 1
-
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
RECRUITING · Phase 1
-
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
RECRUITING · Phase 1
-
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
RECRUITING · Phase 1
-
A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old
ACTIVE NOT RECRUITING · Phase 1
-
KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.